How new ‘molecular scissors’ may give crisper CRISPR – BioNews
|
How new ‘molecular scissors’ may give crisper CRISPR
BioNews Researchers have revealed the structure and action of a new type of ‘molecular scissors’ known as Cpf1, which may improve CRISPR genome editing. Using X-ray crystallography, the team were able to view the three-dimensional structure of Cpf1, a … |
|
How new ‘molecular scissors’ may give crisper CRISPR
BioNews Researchers have revealed the structure and action of a new type of ‘molecular scissors’ known as Cpf1, which may improve CRISPR genome editing. Using X-ray crystallography, the team were able to view the three-dimensional structure of Cpf1, a … |
|
How new ‘molecular scissors’ may give crisper CRISPR
BioNews Researchers have revealed the structure and action of a new type of ‘molecular scissors’ known as Cpf1, which may improve CRISPR genome editing. Using X-ray crystallography, the team were able to view the three-dimensional structure of Cpf1, a … |
|
Glioblastoma ‘ecosystem’ redefined for more effective immunotherapy trials
Science Daily … to a kind of immunotherapy known as checkpoint inhibitors. The resulting gene expression datasets, which are publicly available to researchers, provide comprehensive profiles of glioblastoma characteristics to more accurately guide immunotherapy … |
Scientific American |
Scientists Re-created an Extinct Virus
Scientific American But some scientists fear that it could be revived through what’s known as synthetic biology — the ability to make a virus by putting together by the recipe outlined in its genetic code. The horsepox virus the Canadian team created is not a threat to … |
Motley Fool |
Why CRISPR Therapeutics AG Jumped 11.7% in June
Motley Fool First, CRISPR and MaSTherCell SA announced that they have signed a development and manufacturing agreement related to allogeneic CAR-T therapies. The deal calls for MaSTherCell to handle the development and manufacturing of CRISPR’s compound … |
Madison.com |
Why CRISPR Therapeutics AG Jumped 11.7% in June
Madison.com First, CRISPR and MaSTherCell SA announced that they have signed a development and manufacturing agreement related to allogeneic CAR-T therapies. The deal calls for MaSTherCell to handle the development and manufacturing of CRISPR’s compound … CRISPR Therapeutics and Neon Therapeutics Enter Research CollaborationGlobeNewswire (press release) CRISPR Therapeutics teams up with Neon Therapeutics to develop T cell therapiesInvesting.com Crispr Theraptc (CRSP) Shares Sold by Clough Capital Partners LPSports Perspectives Transcript Daily all 6 news articles » |
Endpoints News |
Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program
Endpoints News After rattling investors with early signs of an immune reaction in a couple of cases as well as an unexpected infusion for a suspected knee bleed, Spark Therapeutics $ONCE says that its early Phase I/II study for its hemophilia B gene therapy is … |